In conclusion, we reported a patient with anti‐MDA5 antibody‐positive DM‐ILD and concluded for the first time that tofacitinib may be an option for anti‐MDA5 antibody‐positive conversion during maintenance therapy. The gene discussed is IFIH1; the disease is dermatomyositis.